Advanced Solutions
for Advanced Pathology
PAX-8 (MRQ-50)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45322 IMPATH PAX-8 RTU M (MRQ-50)
50 Tests
44367 PAX-8 RTU M (MRQ-50)
7 ml Ready To Use
44753 PAX-8 0,1 M (MRQ-50)
100 µl liquid Concentrated
44754 PAX-8 1 M (MRQ-50)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Ovarian carcinoma (non-mucinous
carcinoma), Renal cell carcinoma,
Thyroid carcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
This protein is a member of the paired box (PAX) family of transcription factors. Members of this gene family typically encode proteins which
contain a paired box domain, an octapeptide, and a paired-type homeodomain. This nuclear protein is involved in thyroid follicular cell
development and expression of thyroid-specific genes. Mutations in this gene have been associated with thyroid dysgenesis, thyroid follicular
carcinomas and atypical thyroid adenomas.
PAX-8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes and simple ovarian inclusion
cysts, but not normal ovarian surface epithelial cells. PAX-8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell
carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. Studies have also found PAX-8 expression in renal tubules as well
as renal carcinoma, nephroblastoma, and seminoma. Studies have shown that 98% of clear cell RCCs, 90% of papillary RCCs, and 95% of
oncocytomas are positive for anti-PAX-8, frequencies which are similar to or better than those for anti-PAX-2. Therefore, anti-PAX-8 can be
used as an additional immunohistochemical marker for renal epithelial tumors. Normal lung and lung carcinomas do not express PAX-8. Anti-
PAX-8, combined with organ system-specific markers such as anti-uroplakin, anti-mammaglobin, and anti-TTF-1 can be a very useful panel
to determine the primary site of invasive micropapillary carcinomas from ovary (positive staining) or from bladder, lung, and breast (negative
staining). Anti-PAX-8 is also useful in distinguishing ovarian serous carcinoma from malignant mesothelioma of peritoneum.
Ovarian Carcinomas
PAX-8
WT1
CA-125
CEA
Ovarian CA, Serous
+
+
+
+
Ovarain CA, Mucinous
-
-
-
-
Ovarian CA, Endometrioid
+
-
+
-
Ovarian CA, Clear Cell
+
-
+
-
Micropapillary Carcinomas
PAX-8 Uroplakin
III
CK 20
CK 7 CK, HMW ER Mamma-
globin
WT1
TTF-1
EMA
Bladder
-
+
+
+
-
-
-
-
-
-
Breast
-
-
-
+
-
+
+
-
-
+
Lung
-
-
-
+
-
-
-
-
+
+
Ovary
+
-
-
+
+
+
-
+
-
-
Reference
1. Daisuke N, et al. Mod Pathol. 2008; 21:192-200.
197
